]. C. Guillemette, E. Levesque, M. Harvey, J. Bellemare, and V. Menard, UGT genomic diversity: beyond gene duplication, Drug Metabolism Reviews, vol.142, issue.1, pp.24-44, 2010.
DOI : 10.1159/000106447

]. P. Lazarus, A. S. Blevins-primeau, Y. Zheng, and D. Sun, Potential Role of UGT Pharmacogenetics in Cancer Treatment and Prevention, Annals of the New York Academy of Sciences, vol.66, issue.2, pp.1155-99, 2009.
DOI : 10.1111/j.1749-6632.2009.04114.x

R. Nakajima, H. Fujiwara, T. Yamanaka, M. Fukami, Y. Takamiya et al., Quantitative analysis of UDPglucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers, Drug Metab Dispos, vol.37, pp.1759-68, 2009.

C. P. Strassburg, A. Strassburg, N. Nguyen, Q. Li, M. P. Manns et al., Regulation and function of family 1 and family 2 UDP-glucuronosyltransferase genes (UGT1A, UGT2B) in human oesophagus, Biochem J, issue.2, pp.338-489, 1999.

V. Uchaipichat, P. I. Mackenzie, D. J. Elliot, and J. O. Miners, Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human udp-glucuronosyltransferases, Drug Metab Dispos, vol.34, pp.449-56, 2006.

M. H. Court, S. Hazarika, S. Krishnaswamy, M. Finel, and J. A. Williams, Novel Polymorphic Human UDP-glucuronosyltransferase 2A3: Cloning, Functional Characterization of Enzyme Variants, Comparative Tissue Expression, and Gene Induction, Molecular Pharmacology, vol.74, issue.3, pp.744-54, 2000.
DOI : 10.1124/mol.108.045500

B. Frances, R. Gout, B. Monsarrat, J. Cros, and J. M. Zajac, Further evidence that morphine-6 beta-glucuronide is a more potent opioid agonist than morphine, J Pharmacol Exp Ther, vol.262, pp.25-31, 1992.

. Mutlib, Determination of degradation pathways and kinetics of acyl glucuronides by NMR spectroscopy, Chem Res Toxicol, vol.20, pp.876-86, 2007.

. M. Court, Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system, Drug Metabolism Reviews, vol.7, issue.2, pp.209-233, 2010.
DOI : 10.1124/dmd.106.011387

. M. Court, Isoform???Selective Probe Substrates for In Vitro Studies of Human UDP???Glucuronosyltransferases, Methods Enzymol, vol.400, pp.104-120, 2005.
DOI : 10.1016/S0076-6879(05)00007-8

M. R. Fujiwara, H. Nakajima, M. Yamanaka, T. Katoh, and . Yokoi, Interactions between Human UGT1A1, UGT1A4, and UGT1A6 Affect Their Enzymatic Activities, Interactions between human UGT1A1, UGT1A4, and UGT1A6 affect their enzymatic activities, pp.1781-1788, 2007.
DOI : 10.1124/dmd.107.016402

J. O. Houston and . Miners, Human udp-glucuronosyltransferases: isoform 21

S. M. Donato, J. V. Montero, M. J. Castell, A. Gomez-lechon, and . Lahoz, Validated assay for studying activity profiles of human liver UGTs after drug exposure: inhibition and induction studies, Analytical and Bioanalytical Chemistry, vol.28, issue.1, pp.2251-63, 2010.
DOI : 10.1007/s00216-009-3441-1

K. Rouguieg, N. Picard, F. L. Sauvage, J. M. Gaulier, and P. Marquet, Contribution of the Different UDP-Glucuronosyltransferase (UGT) Isoforms to Buprenorphine and Norbuprenorphine Metabolism and Relationship with the Main UGT Polymorphisms in a Bank of Human Liver Microsomes, Drug Metabolism and Disposition, vol.38, issue.1, pp.40-45, 2010.
DOI : 10.1124/dmd.109.029546

M. Y. Watanabe, N. Nakajima, T. Ohashi, T. Kume, and . Yokoi, Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDPglucuronosyltransferase 1A1, Drug Metab Dispos, pp.31-589, 2003.

J. Trottier, M. Verreault, S. Grepper, D. Monte, J. Belanger et al., Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver, Hepatology, vol.40, issue.5, pp.1158-70, 2006.
DOI : 10.1002/hep.21362

N. Picard, D. Ratanasavanh, A. Premaud, Y. L. Meur, and P. Marquet, IDENTIFICATION OF THE UDP-GLUCURONOSYLTRANSFERASE ISOFORMS INVOLVED IN MYCOPHENOLIC ACID PHASE II METABOLISM, Drug Metabolism and Disposition, vol.33, issue.1, pp.139-185, 2005.
DOI : 10.1124/dmd.104.001651

. Wienkers, Characterization of bropirimine O-glucuronidation in human liver microsomes, Xenobiotica, vol.33, pp.999-1011, 2003.

M. Beaulieu, E. Levesque, D. W. Hum, and A. Belanger, Isolation and characterization of a novel cDNA encoding a human UDPglucuronosyltransferase active on C19 steroids, J Biol Chem, vol.271, pp.22855-62, 1996.

K. J. Miners, J. B. Knights, P. I. Houston, and . Mackenzie, In vitro???in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: Pitfalls and promises, Biochemical Pharmacology, vol.71, issue.11, pp.71-1531, 2006.
DOI : 10.1016/j.bcp.2005.12.019

L. X. He, S. Hesse, G. Hazarika, J. S. Masse, D. J. Harmatz et al., Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam 23

M. H. Court, S. Krishnaswamy, Q. Hao, S. X. Duan, C. J. Patten et al., EVALUATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, MORPHINE, AND CODEINE AS PROBE SUBSTRATES FOR UDP-GLUCURONOSYLTRANSFERASE 2B7 (UGT2B7) IN HUMAN LIVER MICROSOMES: SPECIFICITY AND INFLUENCE OF THE UGT2B7*2 POLYMORPHISM, Drug Metabolism and Disposition, vol.31, issue.9, pp.31-1125, 2003.
DOI : 10.1124/dmd.31.9.1125

O. Miners, Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation, Br J Clin Pharmacol, vol.61, pp.427-466, 2006.

K. E. Dierks, H. K. Stams, G. Lim, H. Cornelius, S. E. Zhang et al., A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry, Drug Metab Dispos, vol.29, pp.23-32, 2001.

N. V. Dixit, P. Hariparsad, J. D. Desai, and . Unadkat, In vitro LC-MS cocktail assays to simultaneously determine human cytochrome P450 activities, Biopharmaceutics & Drug Disposition, vol.30, issue.5, pp.257-62, 2007.
DOI : 10.1002/bdd.552

N. M. Donato, J. V. Jimenez, M. J. Castell, and . Gomez-lechon, FLUORESCENCE-BASED ASSAYS FOR SCREENING NINE CYTOCHROME P450 (P450) ACTIVITIES IN INTACT CELLS EXPRESSING INDIVIDUAL HUMAN P450 ENZYMES, Drug Metabolism and Disposition, vol.32, issue.7, pp.699-706, 2004.
DOI : 10.1124/dmd.32.7.699

B. J. Williams, V. E. Ring, K. Cantrell, D. R. Campanale, S. D. Jones et al., Differential Modulation of UDP-Glucuronosyltransferase 1A1 (UGT1A1)-Catalyzed Estradiol-3-glucuronidation by the Addition of UGT1A1 Substrates and Other Compounds to Human Liver Microsomes, Drug Metabolism and Disposition, vol.30, issue.11, pp.1266-73, 2002.
DOI : 10.1124/dmd.30.11.1266

C. E. Pfeiffer, S. I. Treiling, M. Hoehle, and . Metzler, Isoflavones modulate the glucuronidation of estradiol in human liver microsomes, Carcinogenesis, vol.26, issue.12, pp.2172-2180, 2005.
DOI : 10.1093/carcin/bgi197

J. Y. Liu, L. Ramirez, M. J. House, and . Ratain, The UGT1A1???28 polymorphism correlates with erlotinib???s effect on SN-38 glucuronidation, European Journal of Cancer, vol.46, issue.11, pp.2097-103, 2010.
DOI : 10.1016/j.ejca.2010.04.022

T. J. Zhou and R. P. Tracy, Glucuronidation of Dihydrotestosterone and trans-Androsterone by Recombinant UDP-Glucuronosyltransferase (UGT) 1A4: Evidence for Multiple UGT1A4 Aglycone Binding Sites, Drug Metabolism and Disposition, vol.38, issue.3, pp.431-471, 2010.
DOI : 10.1124/dmd.109.028712

A. V. Uchaipichat, J. B. Galetin, P. I. Houston, J. A. Mackenzie, J. O. Williams et al., Kinetic Modeling of the Interactions between 4-Methylumbelliferone, 1-Naphthol, and Zidovudine Glucuronidation by UDP-Glucuronosyltransferase 2B7 (UGT2B7) Provides Evidence for Multiple Substrate Binding and Effector Sites, Molecular Pharmacology, vol.74, issue.4, pp.74-1152, 2008.
DOI : 10.1124/mol.108.048645

J. F. Sauvage, G. Gaulier, P. Lachatre, and . Marquet, Pitfalls and Prevention Strategies for Liquid Chromatography-Tandem Mass Spectrometry in the Selected Reaction- Monitoring Mode for Drug Analysis, Clinical Chemistry, vol.54, issue.9, pp.54-1519, 2008.
DOI : 10.1373/clinchem.2008.105478

V. C. Peterkin, J. N. Bauman, T. C. Goosen, L. Menning, M. Z. Man et al., Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes, British Journal of Clinical Pharmacology, vol.34, issue.4, pp.458-68, 2007.
DOI : 10.1016/S0278-6915(01)00087-4

Y. Duguay, C. Baar, F. Skorpen, and C. Guillemette, A novel functional polymorphism in the uridine diphosphate???glucuronosyltransferase 2B7 promoter with significant impact on promoter activity, Clinical Pharmacology & Therapeutics, vol.75, issue.3, pp.223-256, 2004.
DOI : 10.1016/j.clpt.2003.10.006

N. N. Djebli, J. P. Picard, Y. L. Rerolle, P. Meur, and . Marquet, Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients, Pharmacogenetics and Genomics, vol.17, issue.5, pp.17-321, 2007.
DOI : 10.1097/FPC.0b013e32801430f8

J. P. Gaganis, K. M. Miners, and . Knights, Glucuronidation of fenamates: Kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and 2B7, Biochemical Pharmacology, vol.73, issue.10, pp.73-1683, 2007.
DOI : 10.1016/j.bcp.2007.01.030